Literature DB >> 7673432

Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance.

M C Villadolid1, N Yokoyama, M Izumi, T Nishikawa, H Kimura, K Ashizawa, T Kiriyama, M Uetani, S Nagataki.   

Abstract

12 of 17, a significant frequency (71%), of untreated Graves' disease patients with no clinical ophthalmopathy showed extraocular muscle (EOM) enlargement by Magnetic Resonance Imaging (MRI). Enlargement was bilateral in 41% and unilateral in 29% in these patients. Apparent enlargements of EOM were also detected, by MRI, in all of 11 Graves' disease patients with clinical ophthalmopathy, bilateral in 73% and unilateral in 27% of patients in this group. Both group showed the inferior rectus muscle as the most frequently involved (56% and 77% respectively). In 16 patients without autoimmune thyroid disorders or ophthalmopathy who served as normal controls, only 2 of these patients (12%) demonstrated mild EOM enlargement. The severity and patterns of EOM enlargement revealed no correlation with abnormalities in serum thyroid function tests or serum thyroidal autoantibodies. In conclusion, a high frequency of Graves' disease patients without clinical eye signs or symptoms harbor EOM abnormalities, as demonstrated by MRI. This suggests that present clinical examination methods are insufficient to diagnose varying degrees of ophthalmopathy in patients with autoimmune thyroid disorders who do not initially present with clinical ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673432     DOI: 10.1210/jcem.80.9.7673432

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

Review 1.  [Endocrine orbit disorders. Pathogenesis, clinical presentation and examination, stage-dependent therapy].

Authors:  A Eckstein; J Esser
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

2.  Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves' orbitopathy--a pilot study at 1.5 T.

Authors:  Eberhard C Kirsch; Achim H Kaim; Marion Gregorio De Oliveira; Georg von Arx
Journal:  Neuroradiology       Date:  2009-09-15       Impact factor: 2.804

3.  [Graves' ophthalmopathy].

Authors:  A Eckstein; J Esser
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

4.  Asymmetric graves ophthalmopathy as a sole manifestation of autoimmune hypothyroidism.

Authors:  Sudhir Kumar Verma; Nirdesh Jain; Sameer Saraf; Shailesh Kumar Singh
Journal:  BMJ Case Rep       Date:  2013-01-03

5.  Association between radioiodine therapy for Graves' hyperthyroidism and thyroid-associated ophthalmopathy.

Authors:  Samer El-Kaissi; Joanne Bowden; Margaret J Henry; Myra Yeo; Bernard L Champion; Peter Brotchie; Geoffrey C Nicholson; Jack R Wall
Journal:  Int Ophthalmol       Date:  2010-04-20       Impact factor: 2.031

6.  99Tcm-octreotide scintigraphy and serum eye muscle antibodies in evaluation of active thyroid-associated ophthalmopathy.

Authors:  B Sun; Z Zhang; C Dong; Y Zhang; C Yan; S Li
Journal:  Eye (Lond)       Date:  2017-04-07       Impact factor: 3.775

Review 7.  Pathogenesis of ophthalmopathy in autoimmune thyroid disease.

Authors:  A E Heufelder
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

8.  Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series.

Authors:  P R K Bhargav; M Sabaretnam; S Chandra Kumar; S Zwalitha; N Vimala Devi
Journal:  Indian J Surg       Date:  2016-06-22       Impact factor: 0.656

9.  Electronic Medical Record Context Signatures Improve Diagnostic Classification Using Medical Image Computing.

Authors:  Shikha Chaganti; Louise A Mawn; Hakmook Kang; Josephine Egan; Susan M Resnick; Lori L Beason-Held; Bennett A Landman; Thomas A Lasko
Journal:  IEEE J Biomed Health Inform       Date:  2018-12-28       Impact factor: 5.772

Review 10.  Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?

Authors:  T Mizokami; M Salvi; J R Wall
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.